Compare Ascendis Pharma A/S (ASND) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Booking Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Booking Holdings Inc trades at $178.64 (market cap $138.23B). The key difference: Booking Holdings Inc is far larger — about 7.8× Ascendis Pharma A/S's market cap, and Booking Holdings Inc pays a 0.9% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BKNG | |
|---|---|---|
Market Cap | $17.74B | $138.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $231.02 |
52-Week Low | $163.32 | $154.13 |
Enterprise Value | $18.11B | $141.15B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Booking Holdings (BKNG) trades at $178.39, up 1.64% with mixed technical signals showing bearish overall momentum but bullish moving averages. The company maintains strong fundamentals with $26.92B revenue and 22.23% net margin in 2025, though Q2 2026 earnings remain pending. Recent news highlights AI integration efforts and travel demand resilience despite geopolitical concerns.
BKNG presents a compelling valuation case with analyst consensus target of $222.81 (25% upside) and no sell ratings. Key risks include AI disruption fears and Middle East tensions, but the company's dominant OTA position and robust cash flow generation support long-term growth prospects in the travel recovery cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
